EKTABS Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 69.88 |
| 52 Week High | SEK 87.93 |
| 52 Week Low | SEK 63.78 |
| Beta | 1.12 |
| 1 Month Change | 0% |
| 3 Month Change | -2.00% |
| 1 Year Change | -13.97% |
| 3 Year Change | -29.49% |
| 5 Year Change | -38.81% |
| Change since IPO | -79.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKTABS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | 1.9% |
| 1Y | -14.0% | -5.8% | 13.2% |
Return vs Industry: EKTABS underperformed the UK Medical Equipment industry which returned -6% over the past year.
Return vs Market: EKTABS underperformed the UK Market which returned 10.9% over the past year.
Price Volatility
| EKTABS volatility | |
|---|---|
| EKTABS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EKTABS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EKTABS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,580 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
| EKTABS fundamental statistics | |
|---|---|
| Market cap | SEK 24.22b |
| Earnings (TTM) | SEK 1.00b |
| Revenue (TTM) | SEK 17.72b |
24.2x
P/E Ratio1.4x
P/S RatioIs EKTABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKTABS income statement (TTM) | |
|---|---|
| Revenue | SEK 17.72b |
| Cost of Revenue | SEK 11.25b |
| Gross Profit | SEK 6.48b |
| Other Expenses | SEK 5.48b |
| Earnings | SEK 1.00b |
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
Feb 21, 2025
| Earnings per share (EPS) | 2.62 |
| Gross Margin | 36.55% |
| Net Profit Margin | 5.65% |
| Debt/Equity Ratio | 76.9% |
How did EKTABS perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield92%
Payout RatioDoes EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarks| Elekta dividend dates | |
|---|---|
| Ex Dividend Date | Mar 06 2025 |
| Dividend Pay Date | Mar 12 2025 |
| Days until Ex dividend | 21 days |
| Days until Dividend pay date | 27 days |
Does EKTABS pay a reliable dividends?
See EKTABS dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 11:05 |
| End of Day Share Price | 2024/10/22 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Elekta AB (publ) is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumit Sayal | AlphaValue |
| Alexander Kleban | Barclays |
| Hassan Al-Wakeel | Barclays |